IR@PKUHSC  > 北京大学第一临床医学院  > 感染疾病科
学科主题临床医学
Lentivector expressing HBsAg and immunoglobulin Fc fusion antigen induces potent immune responses and results in seroconversion in HBsAg transgenic mice
Hong, Yuan1,2; Peng, Yibing2; Mi, Michael5; Xiao, Haiyan2; Munn, David H.2,4; Wang, Gui-qiang1; He, Yukai2,3
关键词Lentivector Hepatitis B virus Vaccines Genetic immunization Immunotherapy Chronic HBV infection
刊名VACCINE
2011-05-17
DOI10.1016/j.vaccine.2011.03.025
29期:22页:3909-3916
收录类别SCI
文章类型Article
WOS标题词Science & Technology
类目[WOS]Immunology ; Medicine, Research & Experimental
资助者NIH ; Georgia Research Alliance (GRA) ; Ministry of Science and Technology, China ; NIH ; Georgia Research Alliance (GRA) ; Ministry of Science and Technology, China
研究领域[WOS]Immunology ; Research & Experimental Medicine
关键词[WOS]T-CELL RESPONSES ; CHRONIC HEPATITIS-B ; DENDRITIC CELLS ; ANTITUMOR IMMUNITY ; IN-VIVO ; RECOMBINANT LENTIVECTOR ; THERAPEUTIC VACCINATION ; GENETIC IMMUNIZATION ; INFECTION ; LYMPHOCYTES
英文摘要

Even though hepatitis B virus(HBV) vaccines effectively prevent new cases of HBV infection, with approximately 350 million patients worldwide, chronic HBV infection remains a major health problem because of the associated complications (such as liver cirrhosis and hepatocellular carcinoma) and the limited treatment options. Immunotherapy has the potential to effectively control HBV replication. In this current study, we found that recombinant lentivectors could induce potent HBV surface antigen (HBsAg) specific T cell responses and humoral immune responses. Tagging the HBsAg with immunoglobulin Fc fragment further substantially increased the HBsAg specific immune responses. Remarkably, the HBS-Fc-lv lentivector could effectively break immune tolerance and induce potent HBsAg specific adaptive immune responses in HBsAg transgenic (Tg) mice with low serum level of HBsAg. More importantly, the induction of HBsAg specific immune responses in Tg mice accompanied seroconversion from HBsAg to anti-HBsAg antibody (anti-HBsAb). Our study demonstrated the potential of utilizing lentivector to treat chronic HBV infection following reduction of viral load with antiviral drug therapy. (C) 2011 Elsevier Ltd. All rights reserved.

语种英语
所属项目编号R01 CA116444
资助者NIH ; Georgia Research Alliance (GRA) ; Ministry of Science and Technology, China ; NIH ; Georgia Research Alliance (GRA) ; Ministry of Science and Technology, China
WOS记录号WOS:000291370900017
引用统计
被引频次:12[WOS]   [WOS记录]     [WOS相关记录]
文献类型期刊论文
条目标识符http://ir.bjmu.edu.cn/handle/400002259/60301
专题北京大学第一临床医学院_感染疾病科
作者单位1.Peking Univ, Hosp 1, Dept Infect Dis, Beijing 100034, Peoples R China
2.Georgia Hlth Sci Univ, MCG Canc Ctr, Immunol Immunotherapy Program, Augusta, GA USA
3.Georgia Hlth Sci Univ, Dept Med, Augusta, GA USA
4.Georgia Hlth Sci Univ, Dept Pediat, Augusta, GA USA
5.Harvard Univ, Harvard Coll, Boston, MA 02115 USA
推荐引用方式
GB/T 7714
Hong, Yuan,Peng, Yibing,Mi, Michael,et al. Lentivector expressing HBsAg and immunoglobulin Fc fusion antigen induces potent immune responses and results in seroconversion in HBsAg transgenic mice[J]. VACCINE,2011,29(22):3909-3916.
APA Hong, Yuan.,Peng, Yibing.,Mi, Michael.,Xiao, Haiyan.,Munn, David H..,...&He, Yukai.(2011).Lentivector expressing HBsAg and immunoglobulin Fc fusion antigen induces potent immune responses and results in seroconversion in HBsAg transgenic mice.VACCINE,29(22),3909-3916.
MLA Hong, Yuan,et al."Lentivector expressing HBsAg and immunoglobulin Fc fusion antigen induces potent immune responses and results in seroconversion in HBsAg transgenic mice".VACCINE 29.22(2011):3909-3916.
条目包含的文件
条目无相关文件。
个性服务
推荐该条目
保存到收藏夹
查看访问统计
导出为Endnote文件
谷歌学术
谷歌学术中相似的文章
[Hong, Yuan]的文章
[Peng, Yibing]的文章
[Mi, Michael]的文章
百度学术
百度学术中相似的文章
[Hong, Yuan]的文章
[Peng, Yibing]的文章
[Mi, Michael]的文章
必应学术
必应学术中相似的文章
[Hong, Yuan]的文章
[Peng, Yibing]的文章
[Mi, Michael]的文章
相关权益政策
暂无数据
收藏/分享
所有评论 (0)
暂无评论
 

除非特别说明,本系统中所有内容都受版权保护,并保留所有权利。